Biological Safety Testing Market Size
The global biological safety testing market was valued at USD 6.64 billion in 2025 and is projected to reach nearly USD 16.25 billion by 2033, growing at a CAGR of 12.6% during the forecast period from 2026 to 2033.
Biological Safety Testing Market Summary and Scope
| Metrics | Details |
| Market CAGR | 12.6% |
| Segments Covered | By Product, By Application, By Test, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Biological Safety Testing Market Dynamics and Trends
The biological safety testing market growth is driven by the rapidly increasing pharmaceutical and biotechnology industries, along with increasing investments, and rising production of new biologics due to the high disease burden.
Rising drug approvals by the U.S. FDA will create huge demand for biological safety testing
The global biological safety testing market is witnessing strong growth due to the rapid expansion of biopharmaceutical production, increasing development of vaccines, cell therapies, and gene therapies, and rising regulatory requirements for product safety and quality assurance. Growing investments in biologics research and manufacturing have significantly increased the demand for sterility, endotoxin, bioburden, and viral safety testing solutions across pharmaceutical and biotechnology companies. In addition, stringent compliance standards imposed by regulatory authorities such as the FDA, EMA, and WHO are compelling manufacturers to adopt advanced biological safety testing methods to ensure product integrity and patient safety.
The market is also benefiting from increasing outsourcing of testing services to specialized contract research organizations (CROs), along with the adoption of automated and rapid microbiological testing technologies that improve efficiency and accuracy. However, high implementation costs associated with advanced testing instruments and laboratory infrastructure remain a major challenge for small and mid-sized manufacturers. Additionally, the shortage of skilled professionals capable of handling complex biological safety testing procedures and strict regulatory validation requirements may limit market expansion in certain regions. Despite these challenges, growing healthcare expenditure, rising biosimilar production, and expanding biotechnology industries in emerging economies are expected to create significant growth opportunities for the market during the forecast period.
Lack of skilled professional is likely to hinder the market growth
However, lack of skilled professional for conducting biological safety testing procedure and the biological safety process is quite time consuming and complex which is expected to hinder the market growth.
Biological Safety Testing Market Segmentation Analysis
The reagents and kits segment are expected to hold largest share in this market segment
Reagents are a major component in biological safety testing and are extensively used in research and clinical laboratories. These reagents are antibiotics, attachments & matrix factors, biological buffers, freezing & dissociation reagents, and various reagents. Rapid advancements and modifications in the formulation of reagents and kits are expected to increase their adoption by laboratory technicians, especially in toxicology assessment.
The vaccine and therapeutics segment are expected to hold largest share in this market segment
Vaccine and therapeutics held the largest share. Clearly defined guidelines ensuring the safety of developed vaccines with unaltered therapeutic value and reduced toxicity are among the factors responsible for the largest share held by this segment. Several guidelines and recommendations issued by regulatory authorities, such as the U.S. FDA, about the characterization and qualification of materials used in the production of vaccines for infectious disease indications, are expected to fuel segment growth.
The bioburden testing segment are expected to hold largest share in this market segment
Bioburden Testing Segment is expected to hold the largest share in the test segment of the market over the forecast period. Organizations like the World Health Organization have also released instructions for health managers and health workers on required infrastructures and standard procedures for effective sterilization and decontamination of medical devices. These factors are expected to raise the demand for proper sterilization, which is expected to boost the demand for Bioburden testing as it acts as an efficient tool in the validation of validation and revalidation of sterilization processes, assessment of the efficiency of cleaning processes, routine monitoring of manufacturing processes to ensure safety.
Bioburden testing is an integral part of validation and revalidation of sterilization processes, assessment of the efficiency of cleaning processes, routine monitoring of manufacturing processes, monitoring of raw materials, components, or packaging, and overall environmental monitoring programs—the high adoption rate, to determine bioburden limits in wide-ranging biologics and medical devices. Moreover, the development of new products in the market is expected to accelerate the market studied. For example, in December 2019, the company has launched the BD Kiestra IdentifA system in Europe and Canada, which is used for microbial identification. It has incorporated automated sample processing steps that ensure accuracy and minimal error.
Moreover, there are high bioburden and microbial contamination rates during pharmaceutical and biologics manufacturing, which is expected to drive government and private organizations to improve underlying biological safety practices. Thus, all these practices performed might drive the overall market.
Biological Safety Testing Market Geographical Share
North America region holds the largest market share of global biological safety testing market
North America dominates the Market and is expected to do the same in the forecast period. The United States is expected to contribute majorly to the market growth of this region. Due to the outbreak of COVID-19, the rising R&D activities related to the COVID-19 have impacted positively on the market growth.
The growth of the biological safety testing market in this region can be directly attributed to the growing biotechnology and pharmaceutical industries in the region. The high growth of these industries is further attributable to factors, such as innovative technologies and the presence of favorable government initiatives. Also, the emerging need for validation of drugs and devices process of manufacturing is expected to boost the demand for the market studied. According to the United States Food & Drug Administration (FDA) report, in 2019, the United States had about 4,676 manufacturing sites for drugs.
Additionally, the advanced healthcare infrastructure and rising R&D spending are expected to increase the revenue size further. According to the data of Pharmaceutical Research and Manufacturers of America (PhRMA), in the United States, about USD 83 billion were spent by the pharmaceutical industry on the R&D. Thus, this is expected to boost the market growth over the forecast period.
Biological Safety Testing Companies and Competitive Landscape
The global biological safety testing market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Avance Biosciences, Cytovance Biologics, Eurofins Scientific, Lonza, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Toxikon, and WuXi AppTec, Charles River Laboratories among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In December 2020, Redberry introduced a new product ''Red One Automated Bioburden Detection'' that enables instantaneous bioburden detection of microorganisms and has been designed for water and pharmaceutical testing.
Key Developments
February 2026: Rising focus on biologics safety, vaccine quality assurance, and regulatory compliance accelerated growth in the Biological Safety Testing market across North America and Europe. Companies including Charles River Laboratories, Merck KGaA, and Thermo Fisher Scientific expanded biological safety testing and quality control service portfolios through advanced innovation.
January 2026: Increasing adoption of cell-based assays, rapid microbial detection technologies, and AI-assisted laboratory analytics strengthened efficiency in the market across the United States, Germany, Japan, and China. Biopharmaceutical companies increasingly utilized automated sterility testing and endotoxin detection platforms to improve biologics manufacturing processes.
December 2025: Growing production of vaccines, monoclonal antibodies, and gene therapies accelerated demand for advanced biological safety testing solutions globally. Healthcare and biotechnology organizations expanded testing capabilities for adventitious agent detection, mycoplasma testing, and viral safety assessment.
November 2025: Expansion of regulatory frameworks and biologics manufacturing activities across Asia-Pacific and Europe strengthened deployment of biological safety testing technologies. Pharmaceutical manufacturers increasingly adopted advanced contamination detection and quality assurance systems for biologic products and biosimilars.
October 2025: Rising advancements in rapid sterility testing, PCR-based pathogen detection, and automated quality control technologies improved biological safety testing capabilities through continuous advancements globally. Research organizations focused on next-generation microbial detection systems and high-throughput analytical platforms.
September 2025: Increasing collaborations between pharmaceutical companies, CROs, and biotechnology firms accelerated innovation in biological safety testing solutions worldwide. Companies focused on AI-enabled laboratory workflows, real-time contamination monitoring, and digital quality management systems.
August 2025: Growing awareness regarding biologics safety, regulatory compliance, and contamination prevention strengthened expansion of the Biological Safety Testing market across Europe and Asia-Pacific. Biopharmaceutical manufacturers increasingly adopted advanced analytical testing services for vaccines, recombinant proteins, and cell therapies.
July 2025: Rising investments in biologics manufacturing infrastructure and laboratory automation accelerated growth in biological safety testing technologies globally. Companies including Lonza Group and WuXi AppTec expanded biologics testing and quality assurance capabilities.
June 2025: Increasing focus on biologics quality assurance, vaccine safety, and regulatory-driven pharmaceutical testing supported strong development in the global Biological Safety Testing market. North America remained the leading region, while Asia-Pacific emerged as the fastest growing market driven by expanding biopharmaceutical production, rising vaccine development activities, and increasing healthcare investments.
Biological Safety Testing Market Key Companies to Watch
Lonza
Overview: Lonza is a leading global provider of integrated healthcare solutions. Lonza Group comprises two segments: Pharma, Biotech & Nutrition segment provides a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Specialty Ingredients segment offer custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries. Lonza has entered into a definitive agreement with Bain Capital and Cinven to acquire Lonza's Specialty Ingredients business and operations for an enterprise value of $ 4.57 billion.
Product Portfolio: The Company’s portfolio comprised of include Primary & Stem Cells, CellBioServices, Culture Media & Reagents, 3D Culture Products, ADME & Toxicology, Transfection, Cell Analysis, Electrophoresis, Endotoxin Detection.
The global biological safety testing market report would provide an access to an approx. 61 market data table, 54 figures and 180 pages.
